NCT00613379View on ClinicalTrials.gov

PRO 140 by IV Administration in Adults With HIV-1 Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
HIV Infections
Interventions
DRUG

PRO 140

10 mg/kg PRO 140, one IV dose (N=10)

DRUG

PRO 140

5 mg/kg PRO 140, one IV dose (N=10)

DRUG

Placebo

PBO, one IV dose (N=10)

Trial Locations (1)

10591

Progenics Pharmaceuticals, Inc, Tarrytown

Sponsors

Lead Sponsor

CytoDyn, Inc.
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

CytoDyn, Inc.

INDUSTRY

NCT00613379 - PRO 140 by IV Administration in Adults With HIV-1 Infection | Biotech Hunter | Biotech Hunter